Glemont chewable tablets 5 mg blister No. 30




Montelukast 5 mg chewable tablets are recommended for children aged 6 to 14 years:
as an additional treatment for bronchial asthma in patients with mild to moderate persistent asthma not adequately controlled by inhaled corticosteroids, and in patients with inadequate clinical control of asthma with short-acting β-agonists used as needed; as an alternative treatment to low doses of inhaled corticosteroids for patients with mild persistent asthma who have not had a recent serious asthma attack requiring corticosteroids, and for those patients who are intolerant to inhaled corticosteroids; as a prophylaxis of asthma in which exercise-induced bronchospasm is the dominant component; for the relief of symptoms of seasonal and perennial allergic rhinitis.Composition
Active ingredient: montelukast;
1 tablet contains montelukast sodium equivalent to montelukast 5 mg;
Excipients: microcrystalline cellulose, mannitol (E 421), croscarmellose sodium, hydroxypropylcellulose, magnesium stearate, aspartame (E 951), cherry flavoring.
Contraindication
Hypersensitivity to the components of the drug.
Method of application
The drug should be used by children under adult supervision.
Children aged 2 to 5 years. For patients with asthma and allergic rhinitis (seasonal and perennial), the recommended dose is 1 chewable tablet of 4 mg once daily.
Children aged 6 to 14 years. For patients with asthma and allergic rhinitis (seasonal and perennial), the recommended dose is 1 chewable tablet of 5 mg once daily.
For the treatment of asthma, the chewable tablet should be taken in the evening 1 hour before or 2 hours after a meal. For the relief of symptoms of allergic rhinitis, the time of administration should be selected individually.
Application features
Pregnant women
Montelukast should be used during pregnancy only if considered absolutely necessary.
Children
Do not use in children under 2 years of age.
Drivers
The drug is intended for use in children.
Overdose
There is no information on the treatment of overdose with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks, and in short-term studies, up to 900 mg/day for approximately one week, with no clinically significant adverse reactions.
Treatment is symptomatic.
Side effects
Infections and infestations: upper respiratory tract infections; Nervous system disorders: headache; Gastrointestinal disorders: abdominal pain; General disorders: thirst.Interaction
Montelukast can be administered with other drugs for the prevention or long-term treatment of asthma. In drug-drug interaction studies, the recommended clinical dose of montelukast had no clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinylestradiol/norethindrone 35/1), terfenadine, digoxin, and warfarin.
Storage conditions
Store in a dry place, protected from light, at a temperature not exceeding 25 °C.
Keep out of reach of children.
Shelf life - 2 years.
There are no reviews for this product.
There are no reviews for this product, be the first to leave your review.
No questions about this product, be the first and ask your question.